MB
| Title | Published in | Access level | OA Policy | Year | Views | Downloads | |
|---|---|---|---|---|---|---|---|
| Primary and Acquired Resistance to Immunotherapy with Checkpoint Inhibitors in NSCLC : From Bedside to Bench and Back | BioDrugs |  | 2025 | 54 | 872 | ||
| Case Report : Trametinib in the treatment of patients with metastatic lung adenocarcinoma harboring NF1 mutation : a case series and literature review | Frontiers in oncology | | 2025 | 3 | 125 | ||
| Unveiling the landscape of uncommon EGFR mutations in NSCLC-A systematic review | Journal of thoracic oncology | | 2024 | 167 | 997 | ||
| Management of stage III non-small-cell lung cancer : rays of hope | Exploration of targeted anti-tumor therapy | | 2024 | 71 | 211 | ||
| Decoding the Clinical and Molecular Signatures of EGFR Common, Compound, and Uncommon Mutations in NSCLC : A Brief Report | Journal of thoracic oncology | | 2024 | 47 | 92 | ||
| Rates of febrile neutropenia and its causes in the real world | Future oncology | | 2024 | 31 | 343 | ||
| Bringing immune-checkpoint inhibitors earlier in the management of non-small cell lung cancer | Translational lung cancer research | | 2023 | 100 | 65 | ||
| The evolving role of immune-checkpoint inhibitors in malignant pleural mesothelioma | Journal of clinical medicine | | 2023 | 48 | 126 | ||
| Novel targets for immune-checkpoint inhibition in cancer | Cancer treatment reviews | | 2023 | 102 | 98 |
